Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Completed 1

Sponsor Class

NETWORK 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Leukemia, Myeloid, Acute 16Myelodysplastic Syndromes 9Lung Neoplasms 5Myeloproliferative Disorders 4Leukemia, Myelomonocytic, Chronic 4Sarcoma 3Prostatic Neoplasms 3Ovarian Neoplasms 3Head and Neck Neoplasms 3Breast Neoplasms 3Stomatitis 2Primary Myelofibrosis 2Neoplasm Metastasis 2Multiple Myeloma 2Mucositis 2Melanoma 2Lymphoma, Non-Hodgkin 2Leukemia, Monocytic, Acute 2Leukemia, Lymphocytic, Chronic, B-Cell 2Leukemia, Biphenotypic, Acute 2Disease 2Carcinoma, Non-Small-Cell Lung 2Uveal Melanoma 1Uterine Cervical Neoplasms 1Triple Negative Breast Neoplasms 1Thrombocythemia, Essential 1Squamous Cell Carcinoma of Head and Neck 1Sarcoma, Synovial 1Prostate Cancer Metastatic 1Polycythemia Vera 1

Interventions

Carboplatin 12Bevacizumab 10Radiotherapy 9Paclitaxel 9Erlotinib Hydrochloride 9Pemetrexed 7Docetaxel 5Taxes 4Cisplatin 4pegfilgrastim 3Gemcitabine 3Cetuximab 3Radiotherapy, Conformal 2Filgrastim 2veliparib 1romidepsin 1pegylated granulocyte colony-stimulating factor 1lentiviral minigene vaccine of COVID-19 coronavirus 1Watchful Waiting 1Vinorelbine 1Topotecan 1Thalidomide 1Temozolomide 1Surgical Procedures, Operative 1Sorafenib 1Selenomethionine 1Radiotherapy, Intensity-Modulated 1Radiosurgery 1Radiation 1Pneumonectomy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Adenocarcinoma, Bronchiolo-Alveolar × Injections × Clear all
NCT01107626 2023-07-07

Bevacizumab or Pemetrexed Disodium Alone or In Combination After Induction Therapy in Treating Patients With Advanced Non-Squamous Non-Small Cell Lung Cancer

Eastern Cooperative Oncology Group

Phase 3 Completed
1,516 enrolled 12 charts
Thoracic

Adenocarcinoma of Lung, Adenocarcinoma, Bronchiolo-Alveolar, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡